Literature DB >> 11516925

Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: description of procedures.

S E Back1, B S Dansky, K M Carroll, E B Foa, K T Brady.   

Abstract

An estimated 30% to 50% of cocaine-dependent individuals meet criteria for lifetime PTSD. This comorbidity has detrimental effects on clinical presentation, and treatment course and outcome. Cocaine dependence is associated with increased rates of exposure to trauma, more severe symptoms, higher rates of treatment attrition and retraumatization, and greater vulnerability to PTSD when compared to other substance use disorders. These associations underscore the need for effective treatments that address issues particular to PTSD in a manner tolerable to cocaine-dependent individuals. This article describes a manualized psychotherapy developed specifically for individuals with PTSD and cocaine dependence. Concurrent Treatment of PTSD and Cocaine Dependence (CTPCD) provides coping skills training, cognitive restructuring techniques, and relapse prevention strategies to reduce cocaine use. In-vivo and imaginal exposure therapy techniques are incorporated to reduce PTSD symptom severity. Primary treatment goals include psychoeducation specific to the interrelationship between PTSD and cocaine dependence, and clinically meaningful reductions in cocaine use and PTSD symptomatology. Secondary goals include a reduction in HIV high-risk behaviors and improved functioning in associated areas, such as anger and negative affect management.

Entities:  

Mesh:

Year:  2001        PMID: 11516925     DOI: 10.1016/s0740-5472(01)00181-7

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  27 in total

Review 1.  Epidemiology and management of alcohol dependence in individuals with post-traumatic stress disorder.

Authors:  Elissa McCarthy; Ismene Petrakis
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

2.  Posttraumatic Stress Disorder and Co-Occurring Substance Use Disorders: Advances in Assessment and Treatment.

Authors:  Jenna L McCauley; Therese Killeen; Daniel F Gros; Kathleen T Brady; Sudie E Back
Journal:  Clin Psychol (New York)       Date:  2012-09-01

Review 3.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

Review 4.  Substance abuse in women.

Authors:  Shelly F Greenfield; Sudie E Back; Katie Lawson; Kathleen T Brady
Journal:  Psychiatr Clin North Am       Date:  2010-06

5.  Exposure therapy for posttraumatic stress disorder in a residential substance use treatment facility.

Authors:  Amber M Henslee; Scott F Coffey
Journal:  Prof Psychol Res Pr       Date:  2010-02-01

6.  ASSOCIATIONS BETWEEN POST-TRAUMATIC STRESS DISORDER SYMPTOMS AND ALCOHOL AND OTHER DRUG PROBLEMS: IMPLICATIONS FOR SOCIAL WORK PRACTICE.

Authors:  Shelly A Wiechelt; Brenda A Miller; Nancy J Smyth; Eugene Maguin
Journal:  Practice (Birm)       Date:  2011-09

7.  Combat posttraumatic stress disorder, substance use disorders, and traumatic brain injury.

Authors:  Kathleen T Brady; Peter Tuerk; Sudie E Back; Michael E Saladin; Angela E Waldrop; Hugh Myrick
Journal:  J Addict Med       Date:  2009-12       Impact factor: 3.702

8.  Posttraumatic Stress Disorder and Substance Use Disorders in College Students.

Authors:  Brian Borsari; Jennifer P Read; James F Campbell
Journal:  J College Stud Psychother       Date:  2008-05-01

9.  A preliminary examination of the relationships between posttraumatic stress symptoms and crack/cocaine, heroin, and alcohol dependence.

Authors:  Matthew T Tull; Kim L Gratz; Will M Aklin; C W Lejuez
Journal:  J Anxiety Disord       Date:  2010-01

10.  A cognitive behavioral therapy for co-occurring substance use and posttraumatic stress disorders.

Authors:  Mark P McGovern; Chantal Lambert-Harris; Stephanie Acquilano; Haiyi Xie; Arthur I Alterman; Roger D Weiss
Journal:  Addict Behav       Date:  2009-03-14       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.